Shanghai Pharmaceuticals Holding Co., Ltd. announced that at the annual general meeting held on 27 June 2019, Mr. CHO Man, Mr. LI Yongzhong and Mr. SHEN Bo were duly elected by the Shareholders of the Company as executive Directors of the seventh session of the Board of Directors, Mr. ZHOU Jun, Mr. GE Dawei and Mr. LI An as non-executive Directors of the seventh session of the Board of Directors, Mr. CAI Jiangnan, Mr. HONG Liang, Mr. GU Zhaoyang and Mr. Manson FOK as independent non-executive Directors of the seventh session of the Board of Directors, and Mr. XU Youli and Mr. XIN Keng as Supervisors of the seventh session of the Board of Supervisors, each with effect from 27 June 2019. Mr. WAN Kam To and Mr. TSE Cho Che, Edward ceased to act as Directors and Ms. CHEN Xin ceased to act as an employee representative Supervisor due to the expiry of each of their terms of office as Directors or Supervisor, each with effect from 27 June 2019. Mr. ZHOU Jun, a non-executive director, has been elected by the Board as the chairman of the seventh session of the Board for a term for three years and Mr. GE Dawei, a non-executive director, has been elected by the Board as the vice chairman of the seventh session of the Board for a term for three years, all with effect from 27 June 2019; Mr. XU Youli, a supervisor, has been elected by the board of supervisors as the chief supervisor of the seventh session of the board of supervisors for a term for three years, with effect from 27 June 2019; Mr. ZHOU Jun, a non-executive director, has been elected by the Board as the convener of the Strategy Committee of the Board; Mr. CAI Jiangnan, an independent non-executive director, and Mr. Manson FOK, an independent non-executive director, have been elected by the Board as members of the Strategy Committee of the Board; Mr. CAI Jiangnan, an independent non-executive director, has been elected by the Board as the convener of the Nomination Committee of the Board; Mr. CHO Man, an executive director, and Mr. HONG Liang, an independent non-executive director, have been elected by the Board as members of the Nomination Committee of the Board; Mr. GU Zhaoyang, an independent non-executive director, has been elected by the Board as the convener of the Audit Committee of the Board; Mr. Manson FOK, an independent non-executive director, and Mr. HONG Liang, an independent non-executive director, have been elected by the Board as members of the Audit Committee of the Board; Mr. HONG Liang, an independent non-executive director, has been elected by the Board as the convener of the Remuneration and Assessment Committee of the Board; Mr. GE Dawei, a non-executive director, and Mr. GU Zhaoyang, an independent non-executive director, have been elected by the Board as members of the Remuneration and Assessment Committee of the Board; Mr. CHO Man, an executive director, has been appointed as the president of the Company by the Board for the same term as the seventh session of the Board, with effect from 27 June 2019; and Mr. ZHAO Yong, Mr. LI Yongzhong, Mr. SHEN Bo, Mr. MAO Jianyi, Mr. GU Haoliang, Mr. LIU Dawei and Mr. ZHANG Yaohua have been appointed as the vice presidents of the Company; Mr. SHEN Bo has been appointed as the chief financial officer of the Company; and Mr. LIU Dawei has been appointed as the Board secretary and joint company secretary of the Company by the Board, all for the same term as the seventh session of the Board, with effect from 27 June 2019.